Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 600-606

  Wang, Dongchun ^a   Jiang, Zhenzhou ^a,b   Zhang, Luyong ^a,b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Concurrent administration; Docetaxel; Mechanisms; Sequential administration; Sunitinib malate

Indexed keywords

DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MAPK1 PROTEIN, HUMAN; PYRROLE DERIVATIVE; TAXOID; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOBLOTTING; INDOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PYRROLES; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866280911     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9905-0     Document Type: Article

References (18)

1. Jemal A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53: 5-26.
2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-6.
3. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Onc. 2007;18:x3-x10.
4. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6(9):229-39.
5. Sanofi-Aventis. Taxotere (docetaxel) prescribing information. New York: Sanofi-389 aventis; 2007.
6. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human nonsmall cell lung cancer cells. Clin Cancer Res. 2007;13:3413-22.
7. Davies AM, et al. Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): overcoming hypothesized antagonism. J Clin Oncol. 2007. ASCO annual meeting proceedings part I 2007,25:7618.
8. Saigal B, Gllsson BS, Johnson FM. Dose-dependent and sequencedependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cen carcinoma. Anticancer Drugs. 2008;19:465-75.
9. Mahaffey CM, et al. Schedule-dependent apoptosis in K-ras mutant non-small cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2007;8:548-53.
10. Christensen J. Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. AACR Meeting Abstracts. 2008. p. 1433.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
12. Sweeney CJ, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369-72.
13. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1a/VEGF signaling. Neoplasia. 2006;8:394-401.
14. Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-37.
15. O'Farrell AM, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101:3597-605.
16. Wasylyk C, et al. Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. Cancer Res. 2008;68: 1275-83.
17. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal. 2001;13:777-85.
18. Zhu XF, Liu ZC, Zeng YX. Tyrosine kinase receptor-mediated signal transduction and cancer treatment. Acta Pharm Sin. 2002;37: 229-34.